5 results about "Immunocompromised patient" patented technology

Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advancing the interests of institutions involved in animal and human healthcare.

A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity.

Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.

A method of prophylactic management of an immunocompromised patient with a mask having a fan assembly is provided. The method includes the mask being fitted to a face and covering a nose and mouth of the patient. The mask is secured to a head of the patient with a set of fasteners. The fan assembly is activated with a power supply to exhaust air from the mask at a rate of at least 5 liters per minute of air flow and dispel particulate matter to inhibit pathogens being inhaled by the patient.

A method of prophylactic management of an immunocompromised patient with a mask having a fan assembly is provided. The method includes the mask being fitted to a face and covering a nose and mouth of the patient. The mask is secured to a head of the patient with a set of fasteners. The fan assembly is activated with a power supply to exhaust air from the mask at a rate of at least 5 liters per minute of air flow and dispel particulate matter to inhibit pathogens being inhaled by the patient.